Current studies

Contact Details

Country overview

Filter Options

Studies That Include
Studies Incorporating These Age Groups
Product Name
Status
Study Title Minimum Age Maximum age Studies That Include Status
A Phase 2 Open-Label Study of Continuation Treatment with Combination Pyrimidine Nucleosides in Patients with Thymidine Kinase 2 Deficiency (TK2) - -
All
Active, not recruiting
A Phase 2 Open-Label Study of Continuation Treatment with Combination Pyrimidine Nucleosides in Patients with Thymidine Kinase 2 Deficiency (TK2)
Thymidine Kinase 2 Deficiency Learn More
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis 18 Years -
All
Active, not recruiting
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis
Psoriatic Arthritis, Moderate to Severe Chronic Plaque Psoriasis, Chronic Plaque Psoriasis Learn More
A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice 18 Years -
All
Active, not recruiting
A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice
Plaque Psoriasis Learn More
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 18 Years -
All
Active, not recruiting
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa Learn More
A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) 18 Years 65 Years
All
Active, not recruiting
A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Atopic dermatitis Learn More